501120-06-5

Basic information

• Product Name: {(R)-4-[(1R,3aS,3bR,4R,5aS,10aS,10bS,12S,12aR)-4,12-Dihydroxy-8-(3-hydroxy-benzyl)-10a,12a-dimethyl-1,2,3,3a,3b,4,5,5a,6,8,10,10a,10b,11,12,12a-hexadecahydro-7,8-diaza-dicyclopenta[a,h]phenanthren-1-yl]-pentanoylamino}-acetic acid tert-butyl ester
• CAS NO: 501120-06-5
• Molecular Weight: 649.871
• Mol File: 501120-06-5.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: {(R)-4-[(1R,3aS,3bR,4R,5aS,10aS,10bS,12S,12aR)-4,12-Dihydroxy-8-(3-hydroxy-benzyl)-10a,12a-dimethyl-1,2,3,3a,3b,4,5,5a,6,8,10,10a,10b,11,12,12a-hexadecahydro-7,8-diaza-dicyclopenta[a,h]phenanthren-1-yl]-pentanoylamino}-acetic acid tert-butyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: {(R)-4-[(1R,3aS,3bR,4R,5aS,10aS,10bS,12S,12aR)-4,12-Dihydroxy-8-(3-hydroxy-benzyl)-10a,12a-dimethyl-1,2,3,3a,3b,4,5,5a,6,8,10,10a,10b,11,12,12a-hexadecahydro-7,8-diaza-dicyclopenta[a,h]phenanthren-1-yl]-pentanoylamino}-acetic acid tert-butyl ester(501120-06-5)
• EPA Substance Registry System: {(R)-4-[(1R,3aS,3bR,4R,5aS,10aS,10bS,12S,12aR)-4,12-Dihydroxy-8-(3-hydroxy-benzyl)-10a,12a-dimethyl-1,2,3,3a,3b,4,5,5a,6,8,10,10a,10b,11,12,12a-hexadecahydro-7,8-diaza-dicyclopenta[a,h]phenanthren-1-yl]-pentanoylamino}-acetic acid tert-butyl ester(501120-06-5)

Safety Data

• Hazardous Substances Data: 501120-06-5(Hazardous Substances Data)

Upstream product

• 832729-23-4 (R)-4-{(5R,7R,8R,9S,10S,12S,13R,14S,17R)-7,12-Dihydroxy-2-[1-hydroxy-meth-(E)-ylidene]-10,13-dimethyl-3-oxo-hexadecahydro-cyclopenta[a]phenanthren-17-yl}-pentanoic acid methyl ester 
• 14772-99-7 3-oxo cholic acid methyl ester 
• 637-33-2 3-hydroxybenzylhydrazine 
• 27532-96-3 glycine tert-butyl ester hydrochloride 
• 832729-24-5 (R)-4-[(1R,3aS,3bR,4R,5aS,10aS,10bS,12S,12aR)-4,12-Dihydroxy-8-(3-hydroxy-benzyl)-10a,12a-dimethyl-1,2,3,3a,3b,4,5,5a,6,8,10,10a,10b,11,12,12a-hexadecahydro-7,8-diaza-dicyclopenta[a,h]phenanthren-1-yl]-pentanoic acid 

Relevant articles and documents

Synthesis and biological evaluation of novel steroidal pyrazoles as substrates for bile acid transporters

A series of novel C2-C3 annulated steroidal pyrazoles was synthesized as substrates for bile acid transporters. The pyrazoles were conjugated with drugs and drug surrogates. Their in vitro transport activities were evaluated in human ileal bile acid transporter (hIBAT) and human liver bile acid transporter (hLBAT) systems. The results of synthetic and transporter assay studies are described. A series of novel steroidal pyrazoles was synthesized as substrates for bile acid transporters to explore their potential as drug carriers. The selected pyrazole fused bile acids were further conjugated with drugs and drug surrogates. Their in vitro transport activities were evaluated in human ileal bile acid transporter (hIBAT) and human liver bile acid transporter (hLBAT) expressing Chinese hamster ovary (CHO)-cells and Xenopus laevis oocytes. The results of synthetic efforts and transporter assays studies are described herein.